Industry News (Patents and Technology)

Patents Issued for Technologies that Destroy Cancer Tumors

Published in Gene Therapy Weekly, July 12th, 1999

Calydon, Inc., Sunnyvale, California, announced the issuance of two patents that expand its intellectual property in the area of engineering viruses to replicate in and kill prostate cancer cells.

One U.S. patent claims a modified adenovirus that may be used as a therapeutic to introduce genetic constructs that are toxic to prostate cancer cells in a highly targeted and specific manner. The other patent claims a human prostate-specific transcriptional regulatory sequence, the polynucleotides that comprise such regions, the toxin gene that is controlled by the regulatory sequence, and methods for treating prostate disease using toxin gene constructs.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1999-07-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry